206 related articles for article (PubMed ID: 24222531)
1. Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3.
Kanthala S; Gauthier T; Satyanarayanajois S
Biopolymers; 2014 Jun; 101(6):693-702. PubMed ID: 24222531
[TBL] [Abstract][Full Text] [Related]
2. Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-HER3.
Pallerla S; Naik H; Singh S; Gauthier T; Sable R; Jois SD
J Pept Sci; 2018 Feb; 24(2):. PubMed ID: 29436155
[TBL] [Abstract][Full Text] [Related]
3. Design of novel lipidated peptidomimetic conjugates for targeting EGFR heterodimerization in HER2 + cancer.
Naik H; Gauthier T; Singh S; Jois S
Bioorg Med Chem Lett; 2018 Dec; 28(22):3506-3513. PubMed ID: 30314880
[TBL] [Abstract][Full Text] [Related]
4. Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer.
Kanthala S; Banappagari S; Gokhale A; Liu YY; Xin G; Zhao Y; Jois S
Chem Biol Drug Des; 2015 Jun; 85(6):702-714. PubMed ID: 25346057
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.
Banappagari S; Corti M; Pincus S; Satyanarayanajois S
J Biomol Struct Dyn; 2012; 30(5):594-606. PubMed ID: 22731912
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain.
Banappagari S; McCall A; Fontenot K; Vicente MG; Gujar A; Satyanarayanajois S
Eur J Med Chem; 2013 Jul; 65():60-9. PubMed ID: 23688700
[TBL] [Abstract][Full Text] [Related]
7. A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models.
Singh SS; Mattheolabakis G; Gu X; Withers S; Dahal A; Jois S
Eur J Med Chem; 2021 Apr; 216():113312. PubMed ID: 33667849
[TBL] [Abstract][Full Text] [Related]
8. A conformationally constrained peptidomimetic binds to the extracellular region of HER2 protein.
Banappagari S; Ronald S; Satyanarayanajois SD
J Biomol Struct Dyn; 2010 Dec; 28(3):289-308. PubMed ID: 20919746
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines.
Banappagari S; Ronald S; Satyanarayanajois SD
Medchemcomm; 2011 Jan; 2(8):752-759. PubMed ID: 21887403
[TBL] [Abstract][Full Text] [Related]
10. A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization.
Kanthala SP; Liu YY; Singh S; Sable R; Pallerla S; Jois SD
Oncotarget; 2017 Sep; 8(43):74244-74262. PubMed ID: 29088782
[TBL] [Abstract][Full Text] [Related]
11. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
12. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
13. Design of peptidomimetics for inhibition of HER2 receptor dimerization by a combination of virtual screening, MD simulations, and QSAR in silico methods.
Jamalan M; Zeinali M; Barzegari Asadabadi E
Chem Biol Drug Des; 2013 Apr; 81(4):455-62. PubMed ID: 23006820
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines.
Satyanarayanajois S; Villalba S; Jianchao L; Lin GM
Chem Biol Drug Des; 2009 Sep; 74(3):246-57. PubMed ID: 19703026
[TBL] [Abstract][Full Text] [Related]
15. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
Monsey J; Shen W; Schlesinger P; Bose R
J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
[TBL] [Abstract][Full Text] [Related]
16. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
17. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
Lazrek Y; Dubreuil O; Garambois V; Gaborit N; Larbouret C; Le Clorennec C; Thomas G; Leconet W; Jarlier M; Pugnière M; Vié N; Robert B; Monnet C; Bouayadi K; Kharrat H; Mondon P; Pèlegrin A; Chardès T
Neoplasia; 2013 Mar; 15(3):335-47. PubMed ID: 23479511
[TBL] [Abstract][Full Text] [Related]
18. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
Garner AP; Bialucha CU; Sprague ER; Garrett JT; Sheng Q; Li S; Sineshchekova O; Saxena P; Sutton CR; Chen D; Chen Y; Wang H; Liang J; Das R; Mosher R; Gu J; Huang A; Haubst N; Zehetmeier C; Haberl M; Elis W; Kunz C; Heidt AB; Herlihy K; Murtie J; Schuller A; Arteaga CL; Sellers WR; Ettenberg SA
Cancer Res; 2013 Oct; 73(19):6024-35. PubMed ID: 23928993
[TBL] [Abstract][Full Text] [Related]
19. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
[TBL] [Abstract][Full Text] [Related]
20. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).
Sollome JJ; Thavathiru E; Camenisch TD; Vaillancourt RR
Cell Signal; 2014 Jan; 26(1):70-82. PubMed ID: 24036211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
